Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT01999361
NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Sponsor: Rodolfo Alejandro
View on ClinicalTrials.gov
Summary
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
Official title: Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2009-01
Completion Date
2028-12
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
DRUG
Myfortic
treatment with myfortic
Locations (1)
Diabetes Research Institute
Miami, Florida, United States